Immune checkpoint blockade (ICB) therapy, targeting programmed cell death ligand‐1 (PD‐L1)/programmed cell death protein 1 (PD‐1) axis and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), has exhibited amazing clinical outcomes in various types of cancers. This evidence concerns the gene PDCD1 and cancer.